Non-invasive prenatal testing is
gradually being accepted by pregnant women with high-risk for screening
common fetal chromosomal aneuploidies such as Edward’s syndrome (trisomy
18), Down syndrome (trisomy 21), Turner syndrome (monosomy X) and Patau
syndrome (trisomy 13). Accuracy, safety, and non-invasiveness are the
key factors credited to the acceptance of these tests amongst
gynecologists and expecting mothers related to invasive tests such as
amniocentesis and chorionic villus sampling (CVS). MaterniT21 was the
first NIPT introduced in October 2011 by Sequenom, Inc. of the U.S.
Since then, it has been the leader of the market, accounting for the
biggest share in terms of volume as well as revenue. However, BGI’s
NIFTY is likely to overtake MaterniT21 PLUS in terms of volume in the
global market. Sequenom, Inc. is likely to maintain its leadership
position in North America through 2024. Panorama, verifi, informaSeq,
Harmony, VisibiliT, BambniTest and PrenaTest are the other commercially
available NIPTs for detecting chromosomal abnormalities.
Report Overview @ https://www.transparencymarketresearch.com/next-generation-sequencing-for-non-invasive-prenatal-testing-market.html
Next generation sequencing is used in the
sequencing technologies that immensely parallelize the DNA sequencing
process rather than limited few fragments or to a single of DNA. The
next generation sequencing (NGS) technology permits rapid sequencing and
yields thousands and millions of sequences in single run using next
generation sequencers. Such technologies have been rapidly developing
owing to the constant demand for high-throughput sequencers which
incline to lesser the cost of DNA sequencing.
According to the Department of Biology,
University of Copenhagen, There are almost 7000 rare diseases that have
been reported globally. Although most of them occur with an incidence of
less than one in 2000, in total around 6% of the population suffers
from rare diseases. These rare diseases are mostly caused by changes in
genes, which is presently lack of effective treatment. The quick
advancement of next generation sequencing technology boosts the
discovery of new causative gene for these rare diseases, as well as the
genetic diagnosis in clinic practice. The innovation of cell-free fetal
DNA, coupling with next generation sequencing, makes NIPT possible for
rare diseases. However, for most of the current routine prenatal genetic
testing for rare diseases require collection of fetal samples through
an invasive process, which sometimes might lead to maternal anxiety, or
even lead to miscarriage. Hence, developing an effective method to
perform noninvasive prenatal test (NIPT) for rare diseases is the
crucial challenge to inhibit birth defect in the future.
Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14135
The exponential progress of the NIPT
market is supported by factors such as no risk of miscarriage with NIPT,
high incidence rate of babies born with Down syndrome, and shifting
trend toward child bearing at advanced maternal age. Maternal age is
closely related to the risk of developing a fetus with chromosomal
abnormalities; hence, rising maternal age is likely to contribute to the
increasing incidence of babies born with chromosomal aneuploidies.
Geographically, the market for
non-invasive prenatal testing products has been segmented into North
America, Europe, Asia Pacific, Latin America, and Middle East &
Africa. Europe is the biggest market with more number of cases followed
by North America. Adoption in Asia pacific is lesser due to less
awareness. North America is expected to grow at highest CAGR in the
forecast period. According to Down Syndrome Education (DSE), the
incidence rate for Down syndrome is one in every 830 children births in
the U.S., while the incidence rate is one in every 920 babies born in
Europe, indicating a large potential consumer base for NIPT.
Conventional invasive prenatal genetic tests such as chorionic villus
sampling (CVS) and amniocentesis are related with the risk of
miscarriage; hence, these are being replaced with new non-invasive
prenatal tests. These new NIPTs are based on the analysis of cell-free
DNA floating in the maternal plasma and pose no risk of miscarriage.
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=14135
Some of the market players in this
industry are., Illumina, Inc., Agilent Technologies, Inc, Biomatters,
Ltd., BGI (Beijing Genomics Institute), Pacific Biosciences, Oxford
Nanorpore Technologies, Ltd., Dnastar, Inc., Life Technologies
Corporation, EMC Corporation, Genomatix Software GMBH, Ocimum
Biosolutions, Ltd., Macrogen, Inc., Partek Incorporated, Qiagen N.V.,
Perkinelmer, Inc., Knome, Inc. and GATC biotech AG.
The report offers a comprehensive
evaluation of the market. It does so via in-depth insights,
understanding market evolution by tracking historical developments, and
analyzing the present scenario and future projections based on
optimistic and likely scenarios. Each research report serves as a
repository of analysis and information for every facet of the market,
including but not limited to: Regional markets, technology developments,
types, applications, and the competitive landscape.
No comments:
Post a Comment